


# PHARMACEUTICAL PATENT LAW

**John R. Thomas**

*Professor of Law*  
*Georgetown University Law Center*  
*Washington, DC*



**The Bureau of National Affairs, Inc., Washington, D.C.**

# Summary Table of Contents

Foreword.....	vii
Preface.....	ix
Detailed Table of Contents .....	xii

## **I. Introduction**

1. Introduction to Pharmaceutical Patents.....	3
--	---

## **II. Patent Acquisition**

2. Patent Eligibility .....	29
3. Utility .....	50
4. Novelty .....	84
5. Nonobviousness .....	143
6. The Patent Instrument .....	202
7. Patent Acquisition Procedures .....	241

## **III. Marketing Approval Procedures**

8. Duration of Rights.....	281
9. The FDA Drug Approval Process.....	302
10. The Orange Book.....	327
11. Marketing Exclusivities .....	348

## **IV. Infringement**

12. Scope of Patent Rights.....	377
13. Claim Interpretation and the Doctrine of Equivalents .....	455
14. Parallel Importation.....	491
15. The Experimental Use Privilege .....	522
16. Antitrust Considerations.....	569

**V. International and Comparative Aspects**

17. International and Comparative Patent Law..... 591

18. International and Comparative Data Protection Law..... 625

**Appendix**

List of Documents Included on CD-ROM..... 641

Table of Cases ..... 645

Index ..... 667

# Detailed Table of Contents

Foreword.....	vii
Preface.....	ix
Summary Table of Contents.....	xi

## I. Introduction

1. Introduction to Pharmaceutical Patents.....	3
I. The Drug Patent Debate.....	4
II. Overview of the Patent Law.....	5
III. Overview of the Marketing Approval Process.....	7
IV. A Brief History of Pharmaceutical Patent Law and Food and Drug Law.....	9
A. <i>Roche v. Bolar</i> .....	9
B. The Hatch-Waxman Act.....	12
1. The Statutory Experimental Use Exception....	13
2. Abbreviated New Drug Applications.....	14
3. Certifications for Orange Book-Listed Patents .	15
4. Patent Infringement Proceedings.....	16
5. Patent Term Extension.....	17
6. Marketing Exclusivities.....	18
7. Generic Exclusivity.....	18
8. The Impact of the Hatch-Waxman Act.....	19
C. The Generic Animal Drug and Patent Term Restoration Act.....	19
D. The Prescription Drug User Fee Act.....	20
E. The Uruguay Round Agreements Act of 1995.....	20
F. The FDA Modernization Act.....	20
G. The American Inventors Protection Act of 1999...	21
H. The 2002 FTC Study.....	21
I. The 2003 FDA Regulations.....	23
J. The Medicare Prescription Drug and Modernization Act of 2003.....	23
1. Single 30-Month Stay.....	23
2. Notice of Applications.....	24
3. Counterclaim for Patent De-Listing.....	24
4. Declaratory Judgment Actions.....	24

5. Generic Exclusivity .....	24
6. Notice of Agreements .....	25
K. The Future .....	25

## II. Patent Acquisition

2. Patent Eligibility .....	29
I. Basic Concepts .....	29
II. Product and Process Claims .....	30
A. Scientific Principles .....	31
B. Products of Nature .....	32
C. Living Inventions .....	35
D. Process Claims for New Uses .....	37
III. Types of Pharmaceutical Patent Claims .....	38
A. Drug Substances .....	38
B. Formulations .....	39
C. Chemical Intermediates .....	39
D. Metabolites and Prodrugs .....	40
E. Crystals and Polymorphs .....	41
F. Isomers .....	42
G. Salts .....	43
H. Combination Therapies .....	44
I. Methods of Using .....	44
J. Methods of Making .....	46
IV. Methods of Medical Treatment .....	46
3. Utility .....	50
I. Introduction .....	50
II. Moral Utility .....	53
III. Practical Utility .....	57
IV. Practical Utility for Pharmaceutical Patents .....	60
A. <i>Brenner v. Manson</i> .....	60
B. Leading Case Law of the Court of Customs and Patent Appeals .....	63
C. Leading Case Law of the Federal Circuit .....	65
D. The 1995 PTO Utility Examination Guidelines ...	66
E. The 2001 PTO Utility Examination Guidelines ...	68
V. Recurring Issues .....	70
A. Safety and Efficacy Considerations .....	70
B. Structural Similarity to Compounds With an Established Utility .....	74
C. <i>In Vitro</i> and <i>In Vivo</i> Tests .....	75
D. Human Clinical Data .....	75
E. Chemical Intermediates .....	76
F. Inoperable Species Within a Genus .....	77
G. Assertions of Multiple Utilities .....	78
H. The Utility Requirement in Adversarial Proceedings .....	79
I. The Utility Requirement and Priority Applications .....	81

4. Novelty .....	84
I. Introduction .....	84
II. Anticipation .....	87
A. Genus and Species .....	88
B. The Enablement Requirement .....	92
III. Inherency .....	93
IV. The 35 U.S.C. §102(b) Statutory Bar .....	99
A. “Public Use” Under 35 U.S.C. §102(b) .....	101
B. “On Sale” Under 35 U.S.C. §102(b) .....	104
C. “In This Country” .....	108
D. Experimental Use .....	110
E. Patents .....	114
F. Printed Publications .....	116
V. Abandonment Under 35 U.S.C. §102(c) .....	117
VI. Delayed U.S. Filing Under 35 U.S.C. §102(d) .....	118
VII. Prior Invention Under 35 U.S.C. §102(a) .....	120
VIII. Prior Invention Under 35 U.S.C. §102(g) .....	123
A. Prior Art Under 35 U.S.C. §102(g) .....	124
B. Priority Under 35 U.S.C. §102(g) .....	125
C. Inventive Activity in Foreign Countries .....	125
D. Conception .....	127
E. Reduction to Practice .....	128
F. Diligence .....	130
G. Corroboration .....	132
H. Patent Award to the Second Inventor .....	133
IX. Disclosure in U.S. Patent Applications Under 35 U.S.C. §102(e) .....	138
X. Derivation Under 35 U.S.C. §102(f) .....	141
5. Nonobviousness .....	143
I. Introduction .....	144
II. Prior Art for Nonobviousness .....	144
A. Analogous Arts .....	145
B. 35 U.S.C. §103(c)(1) .....	147
C. The CREATE Act .....	148
III. The Nonobviousness Inquiry .....	150
A. The Historical Standard of Invention .....	150
B. The Modern Standard of Nonobviousness .....	151
C. The Person of Ordinary Skill in the Art .....	156
D. The Prima Facie Case of Obviousness .....	158
E. Motivation to Combine .....	159
F. Disfavored Frameworks for Nonobviousness ....	164
IV. The Secondary Considerations .....	167
A. Commercial Success .....	168
B. Copying .....	171
C. Licenses .....	171
D. Long-Felt Need .....	172
E. Praise and Skepticism .....	173

F. Prior Failures of Others .....	174
G. Unexpected Results .....	175
V. Structural Similarities as Evidence of Obviousness ..	177
A. Introduction .....	177
B. Homologues .....	184
1. Adjacent Homologues .....	184
2. Ring Expansion and Contraction .....	186
3. Remote Homologues .....	188
C. Isomers .....	189
1. Structural Isomerism .....	189
a. Position Isomerism .....	189
b. Tautomers .....	191
c. Stereoisomers .....	192
2. Bioisomerism .....	194
D. Esters .....	195
1. Prior Art Alcohols .....	196
2. Prior Art Free Acids .....	197
E. Analogs .....	198
VI. Product and Process Claims .....	198
6. The Patent Instrument .....	202
I. Enablement .....	204
A. Basic Concepts .....	204
B. Working and Prophetic Examples .....	206
C. Exhibits and Biological Samples .....	208
II. Best Mode .....	208
III. Written Description .....	212
A. New Matter .....	213
B. Originally Filed Claims .....	216
IV. The Claims .....	218
A. Basic Claim Drafting .....	219
1. The Preamble .....	219
2. The Transition Phrase .....	221
3. The Body .....	224
B. Claim Formats .....	225
1. Dependent Claims .....	226
2. Markush Claims .....	227
3. Product-by-Process Claims .....	228
4. Jepson Claims .....	230
5. Functional Claims .....	231
6. Skuballa Claims .....	235
7. First Medical Use and Swiss-Style Claims .....	235
C. Definiteness .....	237
7. Patent Acquisition Procedures .....	241
I. Fundamentals of Patent Prosecution .....	242
A. Preparation of Applications .....	242
B. Provisional Applications .....	243
C. Examination of Applications .....	244

D. Continuing Applications.....	246
E. The Restriction Requirement and Divisional Applications .....	246
F. Publication of Applications .....	247
G. Petition and Appeal .....	249
H. Invention Secrecy Orders.....	250
II. Other PTO Proceedings.....	250
A. Interferences .....	250
B. Protests.....	252
C. Citation of Prior Art .....	253
D. Public Use Proceedings.....	253
III. Post-Grant Proceedings.....	254
A. Certificates of Correction.....	254
B. Disclaimers.....	254
C. Reissue .....	255
D. Reexamination .....	257
1. <i>Ex Parte</i> Reexamination .....	258
2. <i>Inter Partes</i> Reexamination.....	260
E. Intervening Rights .....	261
IV. Abuses of Patent Acquisition Procedures .....	262
A. Double Patenting.....	262
1. Basic Principles.....	262
2. Double Patenting and the Restriction Requirement.....	265
3. Two-Way Double Patenting.....	266
B. Inequitable Conduct.....	268
C. Misjoinder or Nonjoinder of Inventors.....	273
D. Prosecution Laches.....	275

### III. Marketing Approval Procedures

8. Duration of Rights.....	281
I. Fundamentals of Patent Term.....	281
II. Maintenance Fees.....	283
III. The Patent Term Guarantee Act .....	283
IV. Specialized Legislation .....	283
V. The Hatch-Waxman Act .....	284
A. Eligible Patents .....	285
1. Drug Products .....	285
2. Combination Therapies.....	289
3. Metabolites .....	290
4. Medical Devices .....	291
B. Application for Term Extension .....	293
1. Time Limit for Filing .....	293
2. Identity of the Applicant.....	294
3. Contents.....	295
4. Review of the Application .....	296



5. Interim Extensions .....	297
6. Strategic Considerations .....	298
C. Period of Extension .....	298
D. Limitation Upon Scope of Rights .....	299
9. The FDA Drug Approval Process .....	302
I. Marketing Approval for Innovative Drugs .....	302
A. Preclinical Investigations .....	303
B. Investigational New Drug Applications .....	304
1. Phase I Investigations .....	304
2. Phase II Investigations .....	305
3. Phase III Investigations .....	305
4. Treatment INDs .....	305
5. Screening INDs .....	306
C. New Drug Applications .....	306
D. Postmarketing Surveillance/Phase IV Investigations .....	307
II. Marketing Approval for Generic Drugs .....	307
A. FDA Practices Prior to Hatch-Waxman .....	308
B. Abbreviated New Drug Applications .....	309
C. Section 505(b)(2) Applications .....	311
D. Patent Certifications .....	313
E. Section viii Statements .....	314
F. Thirty-Month Stay of Marketing Approval .....	317
1. Multiple 30-Month Stays .....	318
2. Judicial Modification of the 30-Month Period...	321
III. Antibiotics .....	324
10. The Orange Book .....	327
I. Overview of the Orange Book .....	327
II. Patents Appropriate for Orange Book Listing .....	329
A. The Hatch-Waxman Act .....	329
B. FDA Regulations .....	333
1. General Rules .....	333
2. Polymorph Patents .....	336
3. Product-by-Process Patents .....	337
C. Third-Party Patents .....	337
III. The Timing of Patent Listings .....	339
IV. Orange Book Listing Disputes .....	340
A. The Role of the FDA .....	341
B. Delisting Litigation .....	342
1. Pre-2003 Standards .....	342
2. The Medicare Act .....	345
C. FTC Enforcement .....	346
11. Marketing Exclusivities .....	348
I. Marketing Exclusivity Concepts .....	348
II. New Chemical Entity Exclusivity .....	349
III. New Clinical Study Exclusivity .....	352

IV. Generic Marketing Exclusivity .....	354
A. Basic Concepts .....	354
B. Pre-Medicare Act Standards .....	356
1. Entitlement .....	356
2. Timing of Notice .....	359
3. Commencement of the 180-Day Period .....	359
4. Separate Exclusivities for Distinct Dosages and Strengths .....	361
5. Patent-by-Patent Approach .....	362
6. Relationship to Pediatric Exclusivity .....	363
7. Transferability .....	364
C. Standards Under the Medicare Act .....	364
1. Entitlement .....	364
2. Forfeiture .....	365
3. Timing of Notice .....	366
4. Commencement of the 180-Day Period .....	366
5. Product-by-Product Approach .....	366
D. Unresolved Issues .....	367
1. Authorized Generics .....	367
2. Award of Exclusivity for Judgments of Noninfringement .....	369
V. Pediatric Marketing Exclusivity .....	369
VI. Orphan Drug Marketing Exclusivity .....	371

## IV. Infringement

12. Scope of Patent Rights .....	377
I. Basic Concepts .....	378
A. Direct Infringement .....	378
B. Indirect Infringement .....	380
1. Active Inducement .....	381
2. Contributory Infringement .....	382
3. <i>Deepsouth</i> and 35 U.S.C. §271(f) .....	384
4. Bioconversion as Infringement .....	385
C. Process Patents .....	386
1. The Process Patent Amendments Act .....	386
2. Screening Methods .....	389
D. Government Infringers .....	391
1. The Federal Government .....	392
2. The Bayh-Dole Act .....	395
3. State and Local Governments .....	397
II. Infringement Under the Hatch-Waxman Act .....	399
A. Patent Implications of ANDAs and Section 505(b)(2) Applications .....	399
B. Notification of a Paragraph IV Certification .....	401
C. Offers of Confidential Access .....	401
D. Biobatch Data Versus the ANDA Specification ....	402
E. Generic Submissions for Unapproved Uses .....	404

III. Patent Litigation.....	407
A. Subject Matter Jurisdiction .....	407
B. Supplemental Jurisdiction .....	408
C. Personal Jurisdiction .....	409
1. General Principles .....	409
2. Implications of the Hatch-Waxman Act .....	410
D. Venue .....	411
E. Declaratory Judgment .....	412
1. General Principles .....	412
2. Declaratory Judgment Actions in the Hatch-Waxman Framework .....	415
F. The Availability of Jury Trials Under the Hatch-Waxman Act .....	421
IV. Infringement Defenses .....	423
A. Invalidity and Unenforceability .....	423
B. Issue Preclusion .....	424
C. Laches and Estoppel .....	425
D. Licenses .....	426
1. Basic Concepts .....	426
2. Licensee and Assignor Estoppel .....	429
3. Implied Licenses .....	432
4. Shop Rights .....	434
V. Remedies .....	435
A. General Principles .....	435
1. Injunctions .....	436
2. Compensatory Damages .....	436
a. Reasonable Royalties .....	437
b. Lost Profits .....	438
i. “But For” Causation .....	439
ii. Proximate Causation .....	442
iii. The Entire Market Value Rule .....	443
3. Marking .....	445
4. Provisional Rights .....	445
5. Enhanced Damages .....	446
B. Remedies Under the Hatch-Waxman Act .....	449
1. Remedies Available for Infringing Generic Applications .....	449
2. Generic Filings as Willful Infringements .....	449
C. Implications of Generic Market Entry During Patent Litigation .....	451
13. Claim Interpretation and the Doctrine of Equivalents .....	455
I. Claim Interpretation .....	455
A. Basic Concepts .....	455
B. <i>Markman v. Westview Instruments</i> .....	456
C. Canons of Claim Construction .....	458
D. Dictionaries, the Specification, and the <i>Phillips</i> Case .....	462

II. The Doctrine of Equivalents .....	464
A. Basic Concepts .....	464
1. <i>Graver Tank</i> and the Function–Way–Result Standard .....	464
2. <i>Warner-Jenkinson</i> and the Insubstantial Differences Standard .....	467
3. Functional Equivalents .....	469
B. Limitations on the Doctrine of Equivalents .....	470
1. The All Elements Rule .....	471
2. Prior Art Limitations .....	475
3. Prosecution History Estoppel .....	479
4. The Public Dedication Doctrine .....	485
C. The Reverse Doctrine of Equivalents .....	489
14. Parallel Importation .....	491
I. Introduction .....	491
II. FDA Practices With Respect to Importing Prescription Drugs .....	493
A. The Prescription Drug Marketing Act of 1987 .....	493
B. The MEDS Act of 2000 .....	495
C. The Medicare Modernization Act of 2003 .....	496
D. Reform Proposals in the 108 <sup>th</sup> Congress .....	497
1. Registration of Commercial Participants .....	498
2. FDA Approval Status .....	498
3. Eligible Exporting Countries .....	499
4. Imports for Personal Use .....	500
5. The Pedigree Rule .....	501
6. Packaging Requirements .....	501
7. Commingling .....	501
8. Internet Pharmacies .....	502
9. Sales and Pricing Restrictions .....	502
10. Formulation Changes .....	503
11. Reform Prospects in the 109 <sup>th</sup> Congress .....	503
III. Patent Implications of Parallel Importation .....	503
A. The Exhaustion Doctrine .....	503
B. International Exhaustion .....	504
C. Reform Proposals .....	507
D. Potential Legal Issues .....	508
1. The Takings Clause .....	508
2. State and Local Governments .....	513
3. The TRIPS Agreement .....	515
4. Free Trade Agreements .....	516
5. Label Licenses .....	520
15. The Experimental Use Privilege .....	522
I. The Common Law Experimental Use Privilege .....	524
A. Origins of the Experimental Use Privilege .....	524
B. Cases Upholding the Privilege .....	526
C. Experimental Use as a Matter of Remedies .....	529

D. Cases Rejecting the Experimental Use Privilege ..	530
E. The Common Law Experimental Use Privilege in Pharmaceutical Cases .....	536
F. The Common Law Experimental Use Privilege in Academic Settings .....	537
G. Experimental Use Policy .....	541
II. The Statutory Experimental Use Privilege .....	545
A. Introduction to 35 U.S.C. §271(e)(1) .....	545
1. <i>Roche v. Bolar</i> .....	546
2. The Hatch-Waxman Act .....	548
3. Basic Analytical Framework .....	550
B. Application of 35 U.S.C. §271(e)(1) .....	555
1. Manufacture .....	555
2. Preclinical Trials .....	556
3. Clinical Trials .....	557
4. Other Product Testing .....	558
5. Sales .....	558
6. Displays and Demonstrations .....	559
7. Publications and Promotions .....	560
8. Foreign Patenting and Regulatory Approval ..	561
9. Medical Devices .....	562
10. Research Tools .....	566
16. Antitrust Considerations .....	569
I. Introduction .....	569
II. Notice of Patent Settlements .....	571
III. Judicial Treatment of Reverse Payment Settlements ..	572
A. Per Se Illegality .....	573
B. Rule of Reason .....	575
C. Sui Generis Analysis .....	578
D. Concluding Observations .....	584
 <b>V. International and Comparative Aspects</b>	
17. International and Comparative Patent Law .....	591
I. The Paris Convention .....	593
A. National Treatment .....	593
B. Independence of Patents .....	593
C. International Priority .....	594
D. Benefits of Paris Convention Priority .....	595
E. Limitations of the Paris Convention .....	598
II. The Patent Cooperation Treaty .....	598
III. Foreign Filing Licenses .....	600
IV. Regional Agreements .....	601
A. NAFTA .....	601
B. Other Regional Agreements .....	602
V. The TRIPS Agreement .....	603
A. National Treatment and Most-Favored-Nation Status .....	603

B. Minimum Standards of Protection .....	604
C. Compulsory Licenses .....	605
1. TRIPS Agreement Article 31 .....	605
2. The Doha Declaration .....	606
D. Other Provisions .....	607
E. Effective Dates .....	608
1. Pipeline Protection .....	609
2. Exclusive Marketing Rights .....	610
F. Dispute Settlement .....	610
1. India Pharmaceutical Products .....	611
2. Canada Pharmaceutical Products .....	613
G. Debate on the TRIPS Agreement .....	615
VI. Free Trade Agreements .....	615
A. Patent Term Restoration .....	616
B. Data Exclusivity .....	616
C. Confidential Status of Experimental Data .....	617
D. Accelerated Generic Marketing Approval .....	617
E. Experimental Use Privilege .....	618
F. Parallel Importation .....	618
G. Implications .....	618
VII. Comparative Patent Law .....	619
A. Deferred Examination .....	619
B. Experimental Use Privilege .....	620
C. Grace Period .....	621
D. Methods of Medical Treatment .....	622
E. Oppositions .....	622
F. Patent Validity as an Infringement Defense .....	623
G. Priority Principle .....	623
H. Publication of Pending Applications .....	624
I. Scope of Patent Protection .....	624
18. International and Comparative Data Protection Law .....	625
I. International Data Protection Standards .....	627
A. The TRIPS Agreement .....	627
1. Basic Principles .....	627
2. Eligible Data .....	628
3. Protection Against Unfair Commercial Use ....	629
4. Protection Against Disclosure .....	632
B. Free Trade Agreements .....	633
II. Comparative Data Protection Law .....	635
A. The European Union .....	635
1. Introduction .....	635
2. The Pre-2005 6/10 Formula .....	636
3. 2005 and Beyond: The 8+2+1 Formula .....	637
4. Orphan Drugs .....	638
5. The Proposed Pediatric Testing Incentive .....	639
B. Japan .....	639

**Appendix**

List of Documents Included on CD-ROM .....	641
Table of Cases .....	645
Index .....	667